Business Context and Reporting Period
This Form 8-K Current Report was filed by 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) on September 23, 2022. The filing discloses significant corporate governance changes, specifically the appointment of a new Class I Director and the promotion of an existing executive officer.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel appointments and associated compensation arrangements.
Material Changes and Personnel Appointments
Appointment of Noriyuki Kasahara, M.D., Ph.D.
- Role: Appointed as Class I Director and Chair of the Science and Technology Committee.
- Term: Expires at the 2024 annual meeting of stockholders.
- Background: Professor at UCSF with over 30 years of experience in gene therapy and genetic engineering.
- Compensation:
- Annual cash retainer: $40,000.
- Committee Chair additional cash: $10,000.
- Stock Option: 45,000 shares (Initial Option) with an exercise price of $8.06 per share.
- Vesting: 33.3% on the first anniversary, then monthly thereafter.
Promotion of Fred Kamal, Ph.D.
- Role: Promoted from Chief Operating Officer and Chief Technical Officer to President and Chief Operating Officer.
- Compensation Changes:
- Annual base salary increased to $475,000.
- Annual target bonus set at 45%.
- Stock Option: 15,000 shares (Promotion Grant) with an exercise price of $8.06 per share.
- Vesting: 1/48th monthly over 48 months.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of material risks and contingencies. It is a standard disclosure of executive and director compensation and appointments.
Key Facts for Investor Verification
- Stock Price Context: Verify the fair market value of $8.06 per share on September 23, 2022, to assess the dilution impact of the new options.
- Equity Dilution: Confirm the total number of shares authorized under the 2020 Incentive Award Plan to ensure sufficient shares remain for future grants.
- Executive Retention: Review the vesting schedules to understand the retention timeline for the new President and the new Director.
- Board Expertise: Evaluate the strategic value of Dr. Kasahara's specific expertise in gene therapy relative to the company's current pipeline.